UK-based Stabilitech has been recognised by the World Health Organisation (WHO) as a vaccine developer.

Stabilitech board member Dr Drew noted: “The WHO is a pivotal player when it comes to vaccines, it sets all of the guidelines adopted by bio-pharmaceutical companies for vaccines development.

“Being added to the WHO’s list as a recognised vaccine developer is huge news for us and the UK biopharma sector, providing a level of global recognition that Stabilitech is an active player in finding a vaccine for COVID-19.”

This announcement comes a fortnight after the company announced its intentions to raise $6m in order to join the race to develop a vaccine against Covid-19; Stabilitech’s candidate is an oral vaccine OraPro-COVID-19.

“COVID-19 infects the mucous membranes, or linings, of the ear, nose throat and lungs. That is why we are targeting our vaccine to hit COVID-19 where it sits – in mucosal cells. Other vaccines are currently only targeting the systemic immune system, but we know from our research that COVID -19 is a mucosal virus, therefore all vaccine developers should also be looking for a vaccine that targets both mucosal and systemic immunity. This is what OraPro- COVID-19 delivers in a single capsule,” the company’s chairman Wayne Channon explained.

 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.